ATLANTA (September 6, 2016) –– Brad Chapman, Global Head for Strategic Operations and Integration for UCB, an international biopharmaceutical company focusing on the development of medicines to treat severe diseases of the immune system and of the central nervous system, has been appointed to a position on the Women’s Basketball Coaches Association Board of Directors, the WBCA office announced today.
Chapman, who has more than 17 years’ experience in sales and marketing, both nationally and internationally, will occupy one of three positions on the WBCA board reserved for individuals from the public sector who have a demonstrated history of success in business and who by virtue of their experience can be expected to bring unique skill, talent or relationships to the Association. He was appointed to the position by the WBCA board in July. The appointment is effective immediately.
“We are excited that Brad has agreed to join the WBCA team as a member of our Board of Directors,” said WBCA Executive Director Danielle M. Donehew. “The WBCA holds a prominent place in serving our member coaches and in influencing the game. We will rely heavily on Brad’s knowledge and experience in marketing as our board and staff explore new and better ways to more effectively tell the WBCA story.”
Said Chapman: “I am thrilled to be joining the WBCA Board of Directors and contributing to their ambition of not only improving and advancing the game for women but, more importantly, their vision to build excellent people and leaders through the WBCA’s efforts.”
In 2006 Chapman joined UCB, a Belgian-based biopharmaceutical company headquartered in Brussels, and with U.S. operations based in Atlanta. In his current position, Chapman oversees strategic operations and integration for the company’s Neurology Patient Value unit focused on UCB’s epilepsy portfolio of solutions. Known as the Seizure Freedom Mission, this global team seeks to become the patient-preferred partner for individuals suffering from epilepsy, developing individualized solutions for individual patient needs. His previous roles with the company include Head of U.S. Marketing, Epilepsy and Head of Global Marketing, Epilepsy, as well as Head of Global Strategic Marketing across UCB. Prior to joining UCB, Chapman held various sales, advertising, and marketing positions with Eli Lilly and Company, Roche Labs Inc., Eisai Inc. and McCann-Erickson Company.
Chapman earned a Bachelor of Arts in English from Mercer University in Macon, Georgia, and presently serves on the Alumni Board of Directors for the Mercer University College of Liberal Arts. He is a Partners in Leadership certified facilitator and a Hermann International HBDI certified trainer/facilitator.